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Osteoarthritis (OA) is a common age-related disease with complex pathophysiology. It is characterized
by wide-ranging tissue damage and ultimate biomechanical failure of the whole joint. However, signs
of tissue adaptation and attempted repair responses are evident in OA-affected osteochondral tissues.
Highlighted in this review article is the role of bone-resident mesenchymal stem cells (MSCs) in these
bone remodeling responses, and a proposal that targeting MSC activities in OA subchondral bone could
represent a novel approach for intrinsic joint regeneration in OA. The development of these therapies will
require better understanding of MSC proliferation, migration and differentiation patterns in relation to
OA tissue damage and further clarification of the molecular signaling events in these MSCs during disease
progression.
Lay abstract: Osteoarthritis (OA) is a joint disorder, in which the cartilage, the underlying bone and
other joint tissues are affected. Recent evidence demonstrating attempted repair responses in these OA
tissues challenges the traditional view of OA as a degenerative disorder. Signs of tissue regeneration are
particularly evident in the bone located directly underneath the damaged cartilage, where increased stem
cell activity has been observed. Targeting these stem cells could represent a novel approach for intrinsic
joint regeneration in OA. To progress with developing these novel therapies, a better understanding of
stem cell function in normal and OA joint tissues is needed.
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Clinicopathological considerations
Osteoarthritis (OA) is the most common form of chronic joint disease in man and represents the leading cause of
pain and disability with increased prevalence due to aging populations [1]. It has a complex pathophysiology and in
its final stages it is characterized by chronic pain and stiffness, which is linked to variable levels of inflammation and
severe cartilage loss, all ultimately leading to joint failure. Despite the high prevalence of OA and its association with
the aging process [2], it still remains an idiopathic and poorly understood condition. OA is an active and progressive
disease, which in comparison to rheumatoid arthritis has no effective disease-modifying drug therapy. At the clinical
stage, conventional symptomatic treatments (pain analgesics, intra-articular corticosteroids injections, glucosamine
and/or chondroitin sulfate, chondroprotective drugs) have little effect on OA progression, with joint replacement
ultimately being the only option to restore function and alleviate pain.
OA has long been considered a disease of the cartilage but now it is acknowledged as a disease of the whole
joint, including closely linked alterations in cartilage, synovium and subchondral bone [3]. The synovium consists
of the synovial membrane which encapsulates the joint providing structural support, synovial fluid for appropriate
lubrication and nutrients essential for normal joint function [4]. Subchondral bone has been defined in a number
of ways but is generally referred to as any bone component distal to calcified cartilage and is separated into two
separate anatomic entities: the subchondral plate, consisting of cortical bone underlying the calcified cartilage and
the subchondral trabecular bone [5].
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Figure 1. MRI of knee osteoarthritis showing bone
marrow lesion.
It is now recognized that the OA process can start in various joint structures including ligaments, menisci or
in the bone where the latter has been termed as osteogenic OA [6]. Whether cartilage damage in OA affects the
underlying bone or vice versa is still a matter of debate but emerging evidence emphasizes the importance of bone
involvement in OA progression. For example, some of the hallmarks of OA include an increase in bone volume and
the thickness of subchondral bone [7] as well as the increased number of trabeculae and altered mineralization [8,9].
Another important feature implicating bone involvement in OA is the formation of bone cysts, and the appearance
of bone marrow (BM) lesions and osteophytes [5]. BM lesions (BMLs) are usually identified by ill-defined high
signal on MRI and comprise of edema, necrosis and fibrosis (Figure 1). They have received increased attention
lately due to their ‘almost exclusive’ association with cartilage degradation and alteration of the articular surface in
OA [10]. Osteophytes on the other hand, are fibrocartilage-capped bony outgrowths and a source of pain and loss
of joint function [11]. It remains unclear whether the occurrence of all of these bone changes in OA is due to a
pathological process or functional adaptation.
Mesenchymal stem cells & bone remodeling in OA
During disease progression, the aforementioned structural changes in OA bone are a predictable consequence
of alterations in the cell-mediated bone remodeling process. Bone remodeling is an active and dynamic process
that depends upon the tightly regulated balance between bone formation and bone resorption [12]. The key
cellular players in bone remodeling are osteoclasts; the main bone resorbing cells and osteoblast lineage cells;
mesenchymal stem/stromal cells (MSCs) and their descendants, osteoblasts and osteocytes (Figure 2A). The
molecular communication between the cells involved in this coordinated process plays a pivotal role in maintaining
bone homeostasis and repair [13]. Bone remodeling is believed to commence at the inner bone surface where signals
induced by microdamage or increased mechanical load initiate bone resorption by the osteoclasts. Bone resorption
is regulated by a balanced signaling pathway composed of OPG, RANKL and its receptor; RANK [14]. Following
bone resorption, abundant factors such as TGF-β [15] and IGF-1 [16] are secreted into the BM environment and
recruit MSCs to the remodeling site where they progressively commit to the osteoblast lineage for subsequent new
bone formation, thus coupling bone remodeling spatially and temporally [17]. Bone remodeling activity in OA
subchondral bone is shown on Figure 2B.
MSCs were first described as a rare BM-derived adherent population of colony-forming cells with high prolifer-
ative capacity [18]. BM MSCs have multidirectional differentiation potentials, including osteogenic, chondrogenic
and adipogenic and are critical to the bone microenvironment by virtue of their roles in bone remodeling and sup-
porting hematopoiesis [19]. During bone remodeling, MSCs are able to produce soluble OPG, which acts as a decoy
for RANKL by binding to its receptor; RANK, thus inhibiting osteoclastogenesis [20] suggesting their important role
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Figure 2. Bone remodeling process.
(A) Signals involved in bone remodeling and the role of mesenchymal stem cells (MSCs) in these processes. MSCs are
precursors of osteoblasts (black arrow). The process of osteoblastogenesis is inhibited by sclerostin produced by
osteocytes. In concert with osteocytes, MSCs also control osteoclastogenesis via the production of RANKL and OPG
(blue arrow). In OA, osteoclasts release TGF-β from the bone matrix, which modulates MSC activity near the
resorption site. (B) Bone remodeling activity in OA subchondral bone (hematoxylin and eosin staining of
EDTA-decalcified femoral head subchondral bone). OA: Osteoarthritis.
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Figure 3. Mesenchymal stem cell appearance in osteoarthritis subchondral bone showing CD271+ staining in
perivascular (arrow heads) and bone lining (arrows) locations particularly in the areas of newly-formed bone.
not only in bone formation, but also in bone resorption (Figure 2A). In addition, MSCs are immunomodulatory
cells able to regulate adaptive and innate immune responses, which in the BM microenvironment could be seen as
their control of immune cell egress into systemic circulation as well as being a trigger for ‘emergency’ myelopoiesis in
response to acute infection [21]. MSCs are fairly abundant in human trabecular [22,23] and cortical bone cavities [24],
and in the trabecular subchondral bone in OA [25].
There are internationally recognized criteria for defining culture-expandedMSCs [26]. However, culture-expanded
cells are not functionally and transcriptionally equivalent to their in vivo counterparts, notably with regard to bone-
related signaling pathways [27], adhesion receptors and signaling molecules [28] and homing capacity [29]. So far the
low-affinity nerve growth factor receptor/CD271 is considered one of the most specific and reliable markers for
native human BMMSCs [30]. In terms of their topographical distribution in BM cavities, the CD271-positive cells
occupy bone lining and perivascular niches, the latter characterized by the co-expression of the CD146 marker, in
addition to CD271 [31,32]. In OA, the numbers of CD271-positive cells are increased [25], particularly around the
areas of newly formed bone (Figure 3).
MSCs cultured from mouse BM or compact bone share the same surface markers, being positive for CD29,
CD44, CD105 and Sca-1 expression [33]. PDGFR-α and Sca-1 in particular, have been suggested as selective
markers of mouse BMMSCs [29] and commonly used for their prospective isolation from mouse BM [34]. However,
an intracellular intermediate filament, nestin, remains up to now the most commonly used marker of mouse BM
MSCs in many animal model studies [35,36].
MSCs & their progeny in OA bone
MSCs are common residents of all joint tissues, including synovial tissue and fluid [37] as well as bone [23,24]. Since
the focus of this review is OA subchondral bone compartment, and MSCs found in other joint tissues have been
extensively reviewed elsewhere [38], the following discussion will be specific to MSCs resident in the BM or bone of
OA patients.
One of the earliest studies on this issue was carried out by Murphy et al. which reported that MSCs in OA BM
remote from the site of damage had reduced chondrogenic and adipogenic potentials [39]. A more recent OA animal
study, in which anterior cruciate ligament transection was used to induce OA and nestin was employed as a marker
for identifying and tracking MSCs, has shown their accumulation and deranged differentiation in OA affected
joints and suggested to be a result of the altered TGF-β availability in these areas [40]. The high concentrations
of TGF-β are released from the subchondral bone during osteoclast-mediated bone resorption, facilitating MSCs
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recruitment [41] (Figure 2A). Interestingly, these alterations in TGF-β availability may be also be responsible for
osteophyte formation in OA. Indeed, an important role in osteophytes development has been similarly attributed
to abnormal mechanical load and TGF-β release [11]. In agreement with the Zhen et al. study, Campbell et al.
have recently shown that the number of resident MSCs in affected human OA bone (in the BML areas) was also
increased compared with non-BML areas but their proliferation and mineralization capacities were reduced [25].
Altered gene expression profiles were also observed in MSCs culture expanded from OA BMLs compared with
nonlesional areas, including RANKL expression [25]. Further studies are needed to validate these findings using
purified uncultured MSCs from OA bone but in accumulation, the available evidence thus far points toward the
notion that OA progression impacts MSC physiology in the affected area and that MSC loss of function may in
fact play a major role in the failed joint repair responses in OA.
Similarly, there is increasing evidence for the abnormal behavior and phenotypes of osteoblasts inOA joints [42,43].
Based on endogenous production of PGE2 by their osteoblasts, OA patients have been categorized into two groups:
low PGE2 and high PGE2 [44,45]. Low PGE2 osteoblasts were shown to favor bone resorption having a low
OPG/RANKL ratio due to high RANKL levels compared with normal osteoblasts, which also correlated with
reduced subchondral bone mass in these patients. In contrast, the high PGE2 groups showed an increase in
subchondral bone thickness and higher OPG/RANKL ratio in osteoblasts [44]. Osteoarthritic osteoblasts were also
reported to have increased levels of TGF-β [46], alkaline phosphatase, osteocalcin and COL1A1/COL1A2 mRNA
ratio [47] as well as altered mineralization potential and a dramatic variation of calcium/ phosphate ratio [48].
Further down osteogenesis pathway, the osteocytes; that represent embedded and terminally differentiated os-
teoblasts, also control bone remodeling including both formation and resorption [49]. They are the main source
of RANKL [50] indicating their major role in bone resorption (Figure 2A). Indeed, mouse model studies pro-
vided strong evidence that the osteocyte network enhances bone resorption and inhibits bone formation under
physiological conditions [51]. RANKL expression is further induced in the viable osteocytes neighboring the site
of microdamage [52] leading to increased osteoclast formation at these sites. Another phenomenon, osteocytic
osteolysis that refers to osteocytes’ own potential to remodel their perilacunar and canalicular matrix by removing
and replacing bone, represents a direct mechanism by which osteocytes can resorb bone and actively contribute to
mineral homeostasis [53,54]. In a recent study perilacunar remodeling dysregulation was shown to be important in
the pathogenesis of glucocorticoid-induced osteonecrosis [55].
There is not yet enough evidence to support the idea that osteocytic osteolysis is involved in OA pathophysiology,
but due to the extent of the osteocytes network, this process in our opinion merits further consideration. On the
other hand, osteocyte apoptosis is well recognized in OA as well as abnormal osteocyte morphology [48]. Given
the high bone area covered through their lacuno–canalicular network [49] and its vital role for osteocytes’ survival
by providing their nutrients and communication, any changes in the osteocyte network integrity may play a
considerable role in OA progression.
Taking this evidence together, it is possible to suggest that any alterations in MSCs in OA can affect their
descendants in bone chiefly osteoblasts, which are short-living cells immediately involved in bone remodeling.
Osteocytes are longer-living cells [56] and although they are descendants of MSCs, changes in their behavior during
OA progression could be less attributable to the abnormal behavior of MSCs, and be more related to altered
biomechanical loads. Nevertheless, because MSCs are also the progenitors for other lineages (adipogenic and
chondrogenic in addition to osteogenic), this further emphasizes that MSCs can be regarded as a critical cellular
player in the bone microenvironment in OA.
Therapies aimed to restore MSC bone remodeling & other activities in OA
As mentioned above, subchondral bone abnormalities observed in OA, such as subchondral plate thickening, osteo-
phyte formation and particularly BMLs, which are characterized by thicker but less mineralized softer bone, suggest
that the OA process is associated with altered bone remodeling activity around the site of damage. These changes
are often accompanied by raised concentrations of bone degradation products in the blood of OA patients, such
as N- and C-terminal type I collagen telopeptides or amino- and carboxyl-terminal procollagen propeptides of
type I collagen; however the value of measuring these molecules alongside cartilage degradation products as OA
disease biomarkers remains debatable [3]. As the frequency of BMLs increases with disease progression [57], and
subchondral bone MSCs appear to accumulate in these areas, therapeutic interventions aiming to correct MSC
behavior in OA bone could theoretically prevent OA progression. In the sections below we describe how our current
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understanding of the state of MSCs and their descendants in OA subchondral bone could lead to novel approaches
for OA treatment.
Common & new-generation antiresorptives
Common antiresorptive agents such as bisphosphonates have been used in many animal models of OA. While
these studies have demonstrated several improvements in disease activity [58], the clinical results are less clear [59–61].
In contrast to osteoporosis in which osteoclast-driven bone resorption is the pathological process being targeted,
OA is characterized by ‘the spatial and temporal separation of these processes during joint degeneration’ (increased
remodeling during early disease and its reduced rate as the disease progresses) [9]. A more rationalized use of
bisphosphonates in OA therefore requires better understanding of the ‘window of opportunity’ in which these
antiresorptive agents could lead to restoration of normal bone homeostasis, and should take into consideration
their effects on MSCs [62].
Viewing MSCs as central players in controlling bone formation and remodeling as well as hemopoiesis at the site
of OA, it is conceivable that dual action agents such as strontium ranelate may more effectively interfere with the
development of BMLs [63], by reducing excessive local osteoclast activity and also promoting mineralization of the
newly formed bone. Indeed, two recent clinical trials have shown positive structural effects of strontium ranelate
on knee OA, one improving the joint space narrowing [64] and the other reducing the loss of cartilage volumes
concurrent with the decrease of BMLs at 3 years of follow-up [65]. Other antiresorptive agents such as cathepsin K
inhibitors, that target the resorption process specifically without affecting the osteoclasts [66] have shown promising
results in OA animal models [67,68]. These are already in Phase II and III clinical trials for osteoporosis [69] and could
therefore be considered for clinical trials in patients with early OA. Further work is needed to better understand
the effects of all of these agents on the signaling pathways occurring in OA subchondral bone MSCs.
Targeting TGF-β & sclerostin
As previously mentioned, several groups have identified TGF-β as a target molecule for OA modulation [40,70]. It
has been shown to be overproduced by OA osteoblasts and is actively involved in the induction and development
of osteophytes [71]. Based on their previous ground-breaking study [40] on the effects of TGF-β on subchondral
bone MSCs in OA, Zhen et al. subsequently demonstrated that the systemic use of a TGF-β-neutralizing antibody
attenuated OA progression in rodent OAmodels [72]. However, there remains a concern that such TGF-β inhibition
may simultaneously exacerbate cartilage degeneration in OA. In normal joints, TGF-β levels are tightly controlled
in order to maintain healthy cartilage and simultaneously avoid joint fibrosis, osteophyte formation and other
pathological subchondral bone changes. Therefore, further development of anti-TGF-β therapeutics in OA would
require a careful dose titration to ensure no damage to the cartilage and ideally, attenuation of its degeneration [72].
This emphasizes the importance of targeting the osteochondral unit as a whole in OA, as well as both subchondral
bone and overlaying cartilage components as separate entities [9,73]. This is particularly pertinent for advanced OA,
in which the osteochondral junction is breached thus allowing enhanced molecular and cellular communication
between these two tissues.
TGF-β is known to cooperate with Wnt signaling to stimulate both osteoblast and chondrocyte differentiation
in a positive regulatory loop [74]. A major inhibitor of Wnt signaling and consequently, bone formation, is sclerostin
(Figure 2A). Exclusively secreted by osteocytes and hypertrophic chondrocytes, its role in OA is still under debate.
Sclerostin inhibition is currently being evaluated for the treatment of postmenopausal osteoporosis in humans [75]
but its use in OA is controversial. Although it was shown that its loss did not affect cartilage remodeling in a
mouse model of OA [76], other studies have shown that it can promote OA [77]. A recent study by Wehmeyer et al.
raised more concerns when the inhibition of sclerostin led to increased inflammation and joint destruction in
a TNF-dependent rheumatoid arthritis mouse model [78]. Further work is needed to establish the main cellular
targets for sclerostin and its specific effects on subchondral bone MSCs.
Targeting MSC migration
Anumber of interesting observations describingmigration of cells, includingMSCs, across the damaged subchondral
junction and into the synovial fluid [79,80], has led to the development of OA therapies targeting MSC migration.
These studies alluded to the fact that MSC migration from the subchondral bone toward the joint surface may
represent an attempted repair response, and be a factor contributing to increased abundance of MSCs in OA
synovial fluid [80]. Of note, MSC migration from the subchondral bone into a natural fibrin clot is believed to be
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the main mechanism for fibrocartilaginous cartilage repair following microfracture [81], a common procedure for
isolated cartilage defect treatment in early OA.
More recent evidence suggests that migration of MSCs along chemokine gradients created along thinned
cartilage fissures and other breaks in the osteochondral junction, may acquire undesirable features such as the loss
of chondrogenic potential [80], thus explaining why these attempts to repair are inefficient. Another study recently
demonstrated chemokine receptor alterations in MSCs derived from BML areas of OA bone, including CXCR4
(the receptor for SDF-1α) [25], suggesting their increased sensitivity to local chemokine gradients emanating from
the synovial fluid. Because SDF-1α levels are increased in OA synovial fluid [82] and it is a catabolic factor for
cartilage homeostasis, inhibition of SDF-1α/CXCR4 signaling has been recently attempted in post-traumatic OA
mouse model showing a partial prevention of bone loss and cartilage degeneration [83]. Future clinical studies are
needed to validate this concept in humans.
Aberrantmigration and escape of endogenous subchondral boneMSCs into the synovial fluid can be also achieved
with the use of barrier membranes in procedures such as matrix-assisted chondrocyte implantation [84], which may
be another mechanism contributing to neocartilage tissue formation in addition to exogenous chondrocytes.
Platelet-rich plasma based approaches
Intra-articular injections of platelet-rich plasma (PRP) have been used in sports medicine for a great number of
years and have shown mixed results, primarily due to a lack of consistency in PRP preparation, characterization and
administration [85,86]. An interesting recent development has been the pioneering administration of intra-osseous
PRP for the treatment of cartilage defects in OA [87]. The mechanism of PRP action in these reports remains unclear
but it is possible to suggest that its direct administration into OA bone enables better retention and higher in situ
concentrations of PRP constituents in subchondral bone areas, allowing more direct action on subchondral bone
MSCs. Active PRP components that may exert beneficial effects on MSCs could include platelet-derived growth
factor, known to enhance MSC proliferation in vivo [88,89], as well as chemokines and anti-inflammatory molecules
such as interleukin receptor antagonist [90], which can influence MSCs retention and their immunomodulatory
activity in subchondral bone areas. More work is needed to dissect the mechanisms of action of these different
molecules on MSCs in the OA bone toward better understanding and a more controlled use of these biological
autologous therapies for OA management.
Targeting BMLs
As MSC abnormalities appear to be most confined to the BML areas of OA bone, these BMLs may be targeted
for direct administration of therapeutic agents into OA bone. While it may be seen as rather invasive in the
OA rheumatology community, MSC and scaffold delivery to the lesional areas of bone is a common procedure
for the treatment of avascular necrosis of the femoral head in the orthopedic field [91]. Furthermore, a novel
procedure termed ‘subchondroplasty’, the delivering of bone fillers and bone matrix substitutes into the BML areas
of bone in knee OA is being increasingly used [92]. While these bone substitutes are aimed at preventing bone
collapse following BML development, it is conceivable that bone matrix loaded with PRP or above-mentioned
pharmacological compounds, may lead to improvement of bone homeostasis in BMLs and therefore, to longer
joint preservation.
It is known that BML volumes change over the course of repeated MRI investigations [93]. This could be due
to the already mentioned intermittent changes in the remodeling activity of subchondral bone MSCs as well as
their previously unappreciated high migratory ability [40]. BML-targeted therapies may therefore be most effective
if combined with intra-articular PRP injections, as shown in a recent study [94], or as an adjunct therapy to current
cartilage resurfacing interventions.
Conclusion
Current therapies for OA treatment focus either on the addition of exogenous MSCs to the affected joint or the
use of scaffolds, with or without MSCs, in order to plug cartilage defects and restore joint surface continuity [84].
While recognizing the importance of subchondral bone abnormalities in OA development, current understanding
of the pathophysiology of subchondral bone MSCs in OA and appreciation of their potential as target cells for
future OA therapies remains limited. Future efforts need to be directed toward better understanding of how
bone-resident MSCs respond to early and later drivers of OA such as biomechanical and biochemical changes in
the bone’s extracellular matrix or the effects of synovial fluid constituents including pro-inflammatory cytokines
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and chemokines, on these MSCs. Having identified potential MSC modifiers such as TGF-β and SDF-1α, next
steps would require development of optimal routes and procedures for their administration that would be as a
consequence of a better appreciation of OA as a disease of the whole joint.
These therapies are likely to act on a broader range of cells, not onlyMSCs, therefore future efforts should present
a holistic approach to subchondral bone OA treatment whereby both mesenchymal- and hematopoietic-lineage
stem cells and their descendants are all considered for simultaneous modulation, taking into account their native
niches and three-dimensional environments.
Future perspective
In contrast to osteoporosis, which is a systemic bone disease, OA is characterized by local and temporal alterations in
bone remodeling activity, inwhichMSCs appear to have a prominent role. Future joint regeneration strategies should
not only aim at restoration of the damaged cartilage, but also at target subchondral bone MSC abnormalities, by
means of pharmacological and biological agents to correct their altered migration, proliferation and differentiation
capacities. These interventions may be most successful in conjunction with novel surgical techniques such as
subchondroplasty.
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Executive summary
 There are spatial and temporal alterations in the bone remodeling processes of osteoarthritis (OA) subchondral
bone that can be therapeutically targeted, in order to restore osteochondral tissue homeostasis.
 Recent evidence demonstrates significant changes in mesenchymal stem cell migration, proliferation and
differentiation potentials in OA subchondral bone, particularly in its damaged areas.
 Correcting mesenchymal stem cell functionality in disease-affected areas of OA bone can represent a novel
strategy for joint regeneration in OA.
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